These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9925515)

  • 1. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
    Borkow G; Arion D; Wainberg MA; Parniak MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
    Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
    J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    Hossain MM; Parniak MA
    J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
    Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
    Arion D; Sluis-Cremer N; Parniak MA
    J Biol Chem; 2000 Mar; 275(13):9251-5. PubMed ID: 10734063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.
    Odriozola L; Cruchaga C; Andréola M; Dollé V; Nguyen CH; Tarrago-Litvak L; Pérez-Mediavilla A; Martínez-Irujo JJ
    J Biol Chem; 2003 Oct; 278(43):42710-6. PubMed ID: 12917424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
    Barnard J; Borkow G; Parniak MA
    Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
    Balzarini J; Pelemans H; Esnouf R; De Clercq E
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):255-60. PubMed ID: 9491916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
    Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Larder BA
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
    Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
    Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
    Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
    J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.